Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting.

We did not observe any significant effect of msR4M-L1 administration on body weight, plasma total cholesterol, triglyceride levels, or blood leukocyte counts, although lymphocytes showed a trend toward reduction in the msR4M-L1-treated group (Supplementary Table 3 , Supplementary Fig. 24 ).

also in 53,322 other papers